Compass Pathways is already in the final stage of development on a psychedelic medicine to treat depression.

After President Donald Trump signed an executive order (1) aimed at fast-tracking research and access to psychedelic therapies as a form of mental-health treatment, investors rushed in — sending some stocks soaring as much as 187% (2) in premarket trading Wednesday.

AtaiBeckley Inc (NASDAQ:ATAI) is among the must-buy penny stocks to invest in now. The stock has gained more than 180% over the past 12 months. On April 17, Guggenheim lifted its price target on AtaiBeckley Inc (NASDAQ:ATAI) to $16 from $11 and reiterated a Buy rating on the stock.

U.S. President Donald Trump this week signed an executive order directing health regulators to speed reviews of psychedelic treatments and inc

The directive is expected to lead to fewer legal hurdles for psychedelic studies, increased funding, and potentially stepped-up rescheduling of the drugs.

Atai Life Sciences (NASDAQ:ATAI) is one of the best multibagger penny stocks to buy according to analysts. On July 29, Oppenheimer initiated coverage of the stock with an ‘Outperform’ rating and a $14 price target. The positive stance comes as the ...

NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic ...